Managing the adverse effects related to immune checkpoint inhibitors
Journal
Journal of Nursing
Journal Volume
65
Journal Issue
3
Pages
88-95
Date Issued
2018
Author(s)
Kuo H.-H.
Abstract
Immune checkpoint inhibitors (ICIs) have become the new posterchild of cancer treatment in recent years largely due to their impressive clinical efficacy. Drugs targeting cytotoxic T- lymphocyteassociated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) antibodies, e.g., ipilimumab (Yervoy?), pembrolizumab (Keytruda?), and nivolumab (Opdivo?) reinvigorate cytotoxic T cells to kill cancer cells in patients. Despite the impressive clinical benefits, ICIs may induce immunerelated adverse events (irAE) of the skin, gastrointestinal tract, liver, endocrine, and lung with a wide spectrum of severity. Rare but severe irAEs of critical organs such as the heart and central nervous system have also been reported. Clinical practitioners must recognize the early signs and symptoms of irAE as well as related management strategies. ? 2018 Lippincott Williams and Wilkins. All rights reserved.
Subjects
Immune checkpoint inhibitors; Immune-related adverse effect
SDGs
Other Subjects
CTLA4 protein, human; cytotoxic T lymphocyte antigen 4; ipilimumab; monoclonal antibody; nivolumab; pembrolizumab; programmed death 1 receptor; antagonists and inhibitors; human; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; CTLA-4 Antigen; Humans; Ipilimumab; Programmed Cell Death 1 Receptor
Publisher
Taiwan Nurses Association
Type
journal article